In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme

Showing 1 to 14 of 14

TitleConsultationTypeConsultation end date
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Draft guidanceTechnology appraisal guidance
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221Draft guidanceTechnology appraisal guidance
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Draft guidanceTechnology appraisal guidance
Overweight and obesity managementQuality standard consultationQuality standard
Intrapartum Care - maternal hyponatremiaDraft guidance consultationNICE guideline
Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381]Draft guidanceTechnology appraisal guidance
Abortion CareDraft guidance consultationNICE guideline
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]Draft guidanceTechnology appraisal guidance
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Draft guidanceTechnology appraisal guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Draft guidanceTechnology appraisal guidance
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Draft guidanceTechnology appraisal guidance
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]Draft guidanceTechnology appraisal guidance
Cardiovascular risk assessment and lipid modificationQuality standard consultationQuality standard
Sparsentan for treating primary IgA nephropathy [ID6308]Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All